Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Fineline Cube Jul 28, 2026
Company Drug

Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter

Fineline Cube Jun 27, 2024

Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...

Company Drug

Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide

Fineline Cube Jun 27, 2024

Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its...

Company Deals

CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development

Fineline Cube Jun 27, 2024

CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of...

Company Drug

J&J Halts Mid-Stage Trial for Tremfya in Giant Cell Arteritis Due to Efficacy Concerns

Fineline Cube Jun 26, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S.-based healthcare company, has reportedly discontinued a...

Company Drug

AstraZeneca’s Tagrisso Wins NMPA Approval for First-Line EGFR-mutated NSCLC Treatment

Fineline Cube Jun 26, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, has announced that it has received another...

Company Deals

Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit

Fineline Cube Jun 26, 2024

Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer...

Policy / Regulatory

China’s NMPA Proposes Expedited Review for Clinically Urgent Overseas Drugs

Fineline Cube Jun 26, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Announcement of the...

Company Deals Digital R&D

Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery

Fineline Cube Jun 26, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company Deals

Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%

Fineline Cube Jun 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised...

Company Drug

Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Jun 26, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...

Company Drug

CSPC Pharmaceutical’s BCMA-Targeted CAR-T Therapy SYS6020 Receives NMPA Clinical Trial Approval

Fineline Cube Jun 26, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval

Fineline Cube Jun 26, 2024

Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...

Company Drug

Jiangsu Simcere Pharmaceutical Wins NMPA Nod for Biosimilar Version of Erbitux

Fineline Cube Jun 26, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a Chinese pharmaceutical company, has announced that it...

Company Deals

Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences

Fineline Cube Jun 26, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Policy / Regulatory

U.S. Lawmakers Question FDA on Discrepancies in Foreign Inspections of China and India

Fineline Cube Jun 25, 2024

U.S. lawmakers have intensified their scrutiny of the FDA’s foreign inspection program, particularly for companies...

Company

Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion

Fineline Cube Jun 25, 2024

Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...

Company Drug

Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial

Fineline Cube Jun 25, 2024

Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...

Company Deals

Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform

Fineline Cube Jun 25, 2024

Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of...

Company Drug

J&J’s Tecvayli Earns NMPA Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jun 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S. healthcare company, has announced that it...

Company Drug

Alebund Pharmaceuticals’ AP306 Earns Breakthrough Designation for Chronic Kidney Disease

Fineline Cube Jun 25, 2024

Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor...

Posts pagination

1 … 374 375 376 … 700

Recent updates

  • InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial
  • Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China
  • Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials
  • GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study
  • Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Company Drug

Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials

Company Drug

GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.